Arcera Life Sciences will pay Innogen Pharmaceuticals a non-refundable EUR 13.6M (US$15M) upfront for exclusive rights to efsubaglutide alfa, a GLP-1 drug approved for type 2 diabetes in China, in selected countries across Africa, Eastern Europe, Latin America and the Middle East. Innogen’s stock exchange filing puts the total potential value above EUR 910M (US$1B), so about 1.5% is paid on signing. The rest depends on local approvals and sales in markets where the drug is not yet approved.
At a glance
- EUR 13.6M(US$15M) non-refundable upfront payment to Innogen (HKEX filing; Fierce Pharma)
- EUR 34.6M(US$38M) upfront plus near-term milestones, the money in sight before sales (HKEX filing; Fierce Pharma)
- EUR 910M+(US$1B+) total potential value, including sales milestones and royalties (HKEX filing; Fierce Pharma)
- 2.2 or 1.8HbA1c reduction at week 24: 2.2 points in the company release, 1.8% against 0.74% on placebo in Fierce Pharma
Deal terms from Innogen’s HKEX announcement and Fierce Pharma; clinical figures are company claims as reported in the release and by Fierce Pharma. EUR at the ECB reference rate of 19 November 2026. Checked 20 November 2026.
Arcera, an Abu Dhabi group that says it sells medicines in more than 100 countries, announced the licence with Innogen (HKEX: 2591) on 19 November. Arcera takes on regulatory filings, market access and sales in the territory; Innogen keeps the rest of the world, Fierce Pharma reports. Innogen’s HKEX announcement sets out the terms: an initial 15-year licence, up to EUR 34.6M (US$38M) in upfront and near-term milestone payments, including the EUR 13.6M (US$15M) upfront, plus sales milestones and tiered royalties of up to a double-digit percentage of net sales, for a total potential value of more than EUR 910M (US$1B), a figure Fierce Pharma also reports. The countries are not named.
The companies describe efsubaglutide alfa as a GLP-1 analogue fused to an antibody Fc fragment, with a half-life of up to 280 hours. It is approved for type 2 diabetes in mainland China and Macao and is on China’s 2025 reimbursement list. Sales in Arcera’s territories start only after local approvals, the release says.
The glucose figures differ by source. The release says clinical studies showed HbA1c reductions of about 2.2 percentage points at week 24. Fierce Pharma reports late-stage data in which the drug, added to metformin, cut HbA1c by 1.8% at 24 weeks against 0.74% on placebo. Neither names the trial behind its number, and FoodEdge has not seen the underlying data.
On weight, the companies claim average losses of 10.6% after 18 weeks of weekly dosing in Chinese adults with overweight or obesity, and 9.7% with dosing every two weeks; Fierce Pharma repeats the weekly figure from the release. Obesity is still under study in China, and a Phase II of monthly dosing in Australia is complete, according to the release.
FoodEdge view: Arcera has bought an option, and approval is the exercise price
Our reading is that this is an option priced at about 1.5% of its headline. Arcera pays EUR 13.6M now; most of the EUR 910M depends on approvals in countries that have not been named and on sales that have not started. For nutrition companies selling into Eastern Europe, the Gulf or Latin America, a cheaper GLP-1 could widen the future user base for companion products, but only once each regulator has acted.
The due diligence question: which countries are in the territory, when are the first filings due, and which HbA1c figure, 2.2 points or 1.8%, will those dossiers carry?
Weighing a food biotech or nutrition deal? Independent technical due diligence, before you sign.
How we checked
- Sources: Arcera and Innogen release, GlobeNewswire, 19 Nov 2026; Innogen HKEX announcement, 19 Nov 2026; Fierce Pharma, 19 Nov 2026.
- Snapshot: 20 November 2026; EUR at the ECB reference rate of 19 November 2026 (US$1.0992).
- Key assumption: “about 1.5%” divides the US$15M upfront by the US$1B floor of a total stated as “over” US$1B, so the true share is 1.5% or lower. Counting all near-term payments, US$38M, the share is about 3.8%.
- Main limit: the territory list, milestone triggers and the trials behind each HbA1c figure are unpublished. The HbA1c figures differ between the release and Fierce Pharma, and FoodEdge did not pick one.
AI tools supported source research and drafting during the editorial process.


